The RAS protooncogene has a central role in regulation of cell proliferation, and point mutations leading to oncogenic activation of Ras occur in a large number of human cancers. Silencing of tumor-suppressor genes by DNA methyltransferase 1 (Dnmt1) is essential for oncogenic cellular transformation by Ras, and Dnmt1 is overexpressed in numerous human cancers. Here we provide new evidence that the pleiotropic regulator of G protein signaling (RGS) family member RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated degradation of Dmnt1 and promoting apoptosis. Employing mouse embryonic fibroblasts from wild-type and RGS6
INTRODUCTION
Regulator of G protein signaling 6 (RGS6) is in the RGS protein family, the members of which function as GTPase-activating proteins for Ga subunits to negatively regulate heterotrimeric G protein signaling. [1] [2] [3] Although aberrant G protein activation has been linked to the initiation and progression of various cancers, 4 the role of RGS proteins in oncogenesis remains unexplored. A link between RGS6 and cancer was first provided when a RGS6 singlenucleotide polymorphism leading to increased RGS6 translation was found to be associated with a significant reduction in bladder cancer risk in humans, especially smokers. 5 Based upon this finding, we undertook studies to examine the role of RGS6 in carcinogenesis as a potential novel tumor suppressor. We found that RGS6 dramatically inhibited growth and induced apoptosis in breast cancer cells, and that RGS6 downregulation correlated with increasing breast tumor grade in human patient samples. 6 We further discovered that RGS6 is required for the ability of the chemotherapeutic agent doxorubicin to activate the ATM-p53-apoptosis pathway in mouse embryonic fibroblasts (MEFs) and cancer cells. 7 Importantly, these actions of RGS6 were independent of its ability to interact with or inactivate G proteins, identifying a novel signaling activity for a member of the RGS protein family.
Here we show that RGS6 is induced by oncogenic Ras and blocks Ras-induced cellular transformation by a novel mechanism involving DNA methyltransferase 1 (Dnmt1). This work was inspired by our previous finding that RGS6 forms complexes with Dnmt1 indirectly by binding to DMAP1 (Dnmt1-associated protein). 8 However, the physiological significance of the RGS6-Dnmt1 association remained unknown. Canonically, Dnmt1 functions to maintain genomic DNA-methylation patterns in proliferating cells. 9 It also methylates CpG islands in promoter regions, an important mechanism for silencing gene expression. 10 Increasing evidence suggests that Dnmt1-dependent, DNA methylation-mediated silencing of tumor-suppressor genes is essential for tumor development and progression, as well as cellular transformation induced by oncogenes, such as Ras. [11] [12] [13] [14] [15] [16] [17] Although increased Dnmt1 expression has been observed in a variety of cancers and occurs in tumors harboring Ras mutations, [18] [19] [20] [21] [22] [23] [24] the mechanism underlying overexpression of Dnmt1 in cancers remains unknown. Here, we identify an essential role for RGS6 in modulating Dnmt1 protein levels by scaffolding Dnmt1 and Tip60 and promoting Tip60-dependent Dnmt1 acetylation, leading to Dnmt1 ubiquitylation and degradation. This study provides new insights into our understanding of the mechanism underlying Ras-induced transformation and identifies novel signaling actions for an RGS protein family member.
RESULTS AND DISCUSSION
To determine the role of RGS6 in Ras-induced oncogenic transformation, we compared Ras-induced colony formation in soft agar (anchorage-independent growth) by wild-type (WT) and RGS6 À / À MEFs. To prevent p53-dependent, irreversible cellular senescence 25 and ensure significant Ras transformation efficiency, MEFs were co-infected with two viruses expressing oncogenic H-Ras(G12V) and dominant negative p53(R175H). H-Ras(G12V)-induced colony formation was greatly enhanced in RGS6 À / À vs WT MEFs (Figures 1a and b, Supplementary Figure S1A ), demonstrating that RGS6 inhibits Ras-induced oncogenic transformation. In addition, Ras-induced cell proliferation was significantly enhanced in RGS6
À / À MEFs (Figure 1c ). Subsequent studies showed that H-Ras(G12V) induced a robust upregulation of RGS6 protein levels in MEFs (Figure 2a) . Thus, RGS6 is induced by Ras and functions as a key negative regulator of Ras-induced cellular transformation and proliferation. These findings provide the first evidence linking a RGS protein family member to oncogeneinduced transformation. Recently, we reported that RGS6 induction by doxorubicin is required for activation of the ATMp53-apoptosis pathway 7 and that RGS6 promotes apoptosis by p53-independent mechanisms in cancer cells. 6 The ability of RGS6 to inhibit Ras-induced transformation was p53-independent as it occurred in cells expressing dominant negative p53. Together, our results suggest that RGS6, like p53, is induced both by genotoxic and oncogenic stimuli and, likely via its pro-apoptotic actions, represents a critical cellular defender against oncogene-induced cellular transformation and subsequent tumorigenesis.
Silencing of tumor-suppressor genes by Dnmt1 is essential for oncogenic transformation by Ras. The possibility that RGS6 negatively regulates Ras-induced transformation by inhibiting Dnmt1 was suggested by our previous finding that RGS6 complexes with Dnmt1 indirectly via DMAP1. 8 Although interaction with RGS6 was found to inhibit the transcriptional repressor activity of DMAP1, 8 we did not investigate the effect of RGS6 on Dnmt1 activity or stability. Given these observations, we hypothesized that RGS6 might suppress cellular transformation by inhibiting Dnmt1. We first examined Dnmt1 protein levels in vector and H-Ras(G12V)-expressing WT and RGS6 À / À MEFs. Consistent with previous reports, 26, 27 H-Ras(G12V) induced upregulation of Dnmt1 protein levels in both WT and RGS6 À / À MEFs were incubated with virus-containing medium for 48 h and subjected to selection with 1.5 mg/ml puromycin and 75 mg/ml hygromycin for 72 h. After selection, MEFs were subjected to a soft agar assay according to a standard protocol, or were plated in triplicate in six-well culture plates (1 Â 10 RGS6 on Dnmt1 expression appears to occur primarily by posttranscriptional mechanisms as loss of RGS6 had little or no effect on Dnmt1 mRNA levels (Supplementary Figure S2) . These findings provide new evidence that RGS6 is a powerful negative regulator of basal and Ras-induced Dnmt1 protein levels. This experiment prompted the question of whether the robust upregulation of Dnmt1 in RGS6 À / À MEFs is causally linked to the enhanced Rasinduced transformation in these cells.
To address this question, we investigated the effect of Dnmt1 inhibition on Ras-induced oncogenic transformation and apoptosis in WT and RGS6
À / À MEFs. Dnmt1 is a multidomain enzyme, which is highly activated by deletion of the replication foci targeting sequence. 28 The activated form of Dnmt1 was subjected to a high-throughput screen using a fluorigenic assay, which identified laccaic acid A (LCA), an anthraquinone natural product, as a direct DNA-competitive inhibitor of Dnmt1. 29 We reasoned that if loss of RGS6 promotes oncogenic transformation due to Dnmt1 upregulation, LCA should impair this response. Figure 2b shows that LCA exerted a significant dose-dependent inhibition of Ras-induced colony formation in RGS6 À / À MEFs, whereas slightly reducing colony formation in WT MEFs at the highest dose used. Similar results were obtained with the non-selective Dnmt1 inhibitor 5-Aza-2 0 -deoxycytidine (5-Aza-dC), 30-32 though 5-Aza-dC did not affect colony formation in WT MEFs at doses sufficient to significantly impair transformation of RGS6
À / À cells (Supplementary Figure S3A) . These results suggest that RGS6 prevents Ras-induced oncogenic transformation through its ability to inhibit Dnmt1.
Dnmt1 silences genes encoding pro-apoptotic proteins that normally function to protect against oncogene-induced transformation. RASSF1A and NORE1A are pro-apoptotic Ras effectors that mediate oncogenic Ras-induced apoptosis. 33 Products of other genes targeted by Dnmt1-mediated gene silencing, such as Fas 34 and Par4, 27 are also pro-apoptotic. Dnmt1 inhibitors 35, 36 or Dnmt1 knockdown 37 induces apoptosis in cancer cells. Therefore, upregulation of Dnmt1, as observed in RGS6
À / À cells, would likely impair Ras-induced apoptosis and promote oncogenic transformation. Consistent with the increase in Dnmt1 protein, expression of pro-apoptotic Dnmt1 target genes FAS, NORE1A and RASSF1A was significantly lower in RGS6 Figures S3B,C) . The related but inactive anthraquinone UI1055 did not affect Ras-induced apoptosis in cells of either genotype (Supplementary Figure S4) . Also, re-expression of RGS6L or the GTPase-activating proteindeficient RGS6(N401V) mutant restored the Ras-induced apoptotic response in RGS6 À / À MEFs (Figure 2f ). Thus, RGS6 prevents Rasinduced apoptosis by Dnmt1-dependent and G protein-independent mechanisms.
The inability of LCA to completely restore Ras-induced apoptosis in RGS6
À / À MEFs could be due to incomplete inhibition of Dnmt1 or reflect the contribution of direct apoptotic actions of RGS6. Indeed, we have shown that Ras induces RGS6 (Figure 2a) , and our previous studies demonstrated that RGS6 possesses potent pro-apoptotic activity. 6 Given that RGS6 is required for Ras-induced apoptosis, we determined the importance of apoptosis in suppression of Ras-induced transformation by RGS6. Figure 2g shows that Z-FAD-FMK, a pan caspase inhibitor, greatly increased H-Ras(G12V)-induced colony formation in soft agar in WT but not RGS6 À / À MEFs. These findings indicate that apoptosis prevents Ras-induced colony formation and that this response is absent in RGS6 À / À MEFs. Together, our results support a model in which RGS6 upregulation by Ras blocks Ras-induced transformation via suppression of Dnmt1 protein expression and inhibition of Dnmt1-mediated antiapoptotic activity as well as through the possible direct, proapoptotic actions of RGS6 (Figure 2h ).
Dnmt1 expression levels were unaltered in RGS6 À / À wholebrain tissue lysates. However, a small but significant increase in Dnmt1 protein levels was detected in specific brain regions including olfactory bulb (Figure 3a) . The olfactory bulb is one site Figure 1 . MEFs were grown in normal culture medium for 2 weeks after antibiotics selection. Cell lysates were then prepared and subjected to immunoblotting as previously described. À / À MEFs was performed in the presence and absence of the indicated concentrations of LCA as described in Figure 1 . (c) Loss of RGS6 promotes silencing of pro-apoptotic Dnmt1 target genes FAS, NORE1A and RASSF1A. For each gene, there was a significant effect (Po0.05) of genotype and transfection condition by two-way ANOVA. H-Ras(G12V) was transiently transfected into MEFs using Lipofectamine 2000 as described. 7 mRNA from control and Ras(G12V)-transfected MEFs was prepared using a Qiagen RNeasy Mini kit (Qiagen, Valencia, CA, USA) and first stand cDNA synthesis was performed with SuperScript III (Invitrogen, Carlsbad, CA, USA). Real-time PCR was carried out using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) according to the manufacturer's protocol. PCR primers used are outlined in Supplementary Table 1 and 18S rRNA was used as an internal control to normalize RNA levels. Ras-induced caspase 3 and poly (ADP-ribose) polymerase (PARP) cleavage (d) and apoptosis (e) are impaired in RGS6 À / À MEFs and partly restored by treatment with LCA. For apoptosis assay, two-way ANOVA revealed a significant effect of genotype (F 1,12 ¼ 127.24; Po0.0001) and drug treatment (F 2,12 ¼ 207.68; Po0.0001). Apoptosis is expressed as a fold increase in enrichment factor (cytoplasmic nucleosomes, that is, cytoplasmic histone-associated DNA fragments) measured with the Roche Cell Death Detection Kit (Roche, Branchburg, NJ, USA). Apoptosis was analyzed 72 h after H-Ras(G12V) transfection. (f) RGS6L and RGS6L N401V rescue restore the impaired Ras(G12V)-induced apoptotic response (methods described in legend of (e) in RGS6 À / À MEFs. Two-way ANOVA revealed a significant effect of RGS6 transfection condition (F 3,16 ¼ 23.13; Po0.0001). Cells were co-transfected with and without H-Ras (G12V) and indicated RGS6 construct using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. (g) Inhibition of apoptosis enhances H-Ras(G12V)/p53(R175H)-induced colony formation in WT but not RGS6 À / À MEFs (n ¼ 9). Two-way ANOVA revealed a significant effect of genotype (F 1,32 ¼ 1047.69; Po0.0001) and drug treatment (F 1,32 ¼ 87.83; Po0.0001). Soft agar colony assays in WT and RGS6 À / À MEFs were performed in the presence and absence of pancaspase inhibitor Z-VAD-FMK (40 mM, Sigma) as described in Figure 1 . (h) Schematic diagram illustrating the role of RGS6 in Ras-induced oncogenic transformation. Oncogenic Ras induces RGS6, which directly induces apoptosis and suppresses Dnmt1 protein expression, thereby impairing Dnmt1 silencing of apoptotic genes. *Po0.05; **Po0.01; ***Po0.001; À / À MEFs. HEK 293T cells were co-transfected with envelope plasmid pVSV-G, packaging plasmid PAX2 and empty viral vector or viral DNA containing shTip60-1 or shTip60-2 (Open Biosystems, Pittsburgh, PA, USA) by electroporation as described. 45 Twenty-four hours after transfection, virus-containing culture medium was collected. WT and RGS6
À / À MEFs were incubated with virus-containing medium for 48 h. Representative immunoblot (upper panel) and summary of multiple experiments illustrating effects of Tip60 knockdown on Dnmt1 protein levels in WT and RGS6 À / À MEFs (lower panel) are shown. Two-way ANOVA revealed a significant effect of genotype (F 1,12 ¼ 23.05; P ¼ 0.0004) and Tip60 knockdown (F 2,12 ¼ 11.84; P ¼ 0.0014). (i) Hypothetical model depicting RGS6 scaffolding of Tip60 and Dnmt1 to facilitate Tip60 acetylation of Dnmt1 and subsequent Dnmt1 polyubiquitylation and degradation. Tissue lysates were prepared and quantified as described previously. 46 Immunoblotting and transfections were performed as previously described. 7 Antibodies used were: RGS6 (prepared in the lab; 7 1:5000); HA (Santa Cruz; 1:1000); Tip60 (Santa Cruz, N17; 1:1000); Dnmt1 (Santa Cruz; 1:1000); GFP (Santa Cruz; 1:2000); His (Santa Cruz; 1:1000); acetylated-lysine (Cell Signaling, Danvers, MA, USA; 1:5000); actin (Sigma; 1:2000); tubulin (Millipore, Billerica, MA, USA; 1:5000). **Po0.01; ***Po0.001 (bonferroni multiple comparisons). Unless otherwise indicated all experiments were performed in triplicate and representative results are shown. Data are presented as mean ± s.e.m. of adult neurogenesis 38 implying RGS6-mediated suppression of Dnmt1 expression is particularly important in replicating cell types. In other studies, we have shown that carcinogen-induced Dnmt1 upregulation is potentiated in RGS6 À / À mice. 39 Together, these findings indicate that RGS6 also controls Dnmt1 protein levels in vivo.
We then undertook experiments to elucidate the mechanisms underlying regulation of Dnmt1 protein levels by RGS6. Our findings suggest that RGS6 negatively regulates basal Dnmt1 protein levels by post-transcriptional mechanisms (Figure 2a,  Supplementary Figure S2) . Indeed, analysis of Dnmt1 protein half-life in cyclohexamide-treated MEFs revealed a remarkable stabilization of Dnmt1 in RGS6
À / À cells (Figure 3b ). In fact, no detectable loss of Dnmt1 expression was seen even after inhibition of protein synthesis for 24 h in the absence of RGS6 (Figure 3b ). Dnmt1 stability is regulated by acetylation-dependent ubiquitylation and deubiquitylation primarily controlled by Tip60, an acetyltransferase, which, through direct acetylation, drives ubiquitylation and degradation of Dnmt1. 40 We hypothesized that RGS6 might recruit Dnmt1 and Tip60 to mediate acetylationdriven degradation of Dnmt1 based upon two intriguing findings. First, we found previously that RGS6 complexes with Dnmt1 through association with DMAP1, an interaction mediated by the GGL (Gg subunit like) domain of RGS6. 8 This association between RGS6 and DMAP1 is necessary for control of Dnmt1 stability because re-expression of full-length RGS6, but not a mutant lacking the GGL domain in RGS6 À / À MEFs restored Dnmt1 expression to WT levels (Figure 3c ). Second, Axin, an atypical member of the RGS protein family, functions as a scaffold for Tip60 and p53 to facilitate p53 acetylation. 41 Indeed, human influenza hemagglutinin (HA)-tagged Tip60 (HA-Tip60) can be co-immunoprecipitated with green fluorescent protein (GFP)-tagged RGS6 (RGS6-GFP) demonstrating that Tip60 and RGS6 form a stable complex when co-expressed in cells (Figure 3d ). To determine whether this association occurs in vivo, we performed co-immunoprecipitation studies in whole mouse brain lysates where both proteins are natively expressed. Lysates from WT and RGS6 À / À mice were subjected to immunoprecipitation with anti-Tip60 and probed for RGS6, Tip60 and Dnmt1. Consistent with our findings in transfected cells, endogenous RGS6 and Tip60 form a complex (Figure 3e) . Importantly, the amount of Dnmt1 that co-immunoprecipitated with Tip60 was greatly reduced in RGS6 À / À lysates. This latter finding indicates that RGS6 is an important scaffolding partner for Dnmt1 and Tip60.
We next investigated which of RGS6's functional domains mediates its association with Tip60. In addition to the RGS domain, conferring its ability to bind and enhance the GTPase activity of Ga subunits, RGS6 possesses DEP (Dishevelled, Egl-10, Pleckstrin homology) and GGL domains necessary for protein-protein interactions including GGL domain-dependent binding to Gb5 and DMAP1. 8, 42, 43 To identify the domains of RGS6 necessary for Tip60 association, we compared the ability of GFP-tagged RGS6 and each of its functional domains to co-immunoprecipitate HATip60 in transfected cells. Both full-length RGS6 and its RGS domain alone, but neither its N-terminal DEP-containing nor GGL domains, co-immunoprecipitated Tip60 (Figure 3f ). These results show that the RGS domain of RGS6 is sufficient to mediate Tip60-RGS6 association. Thus, Tip60 binds directly or indirectly to the RGS domain of RGS6 located adjacent to the GGL domain where Dnmt1 is bound via DMAP1.
The crystal structure of the closely related RGS9:Gb5 complex revealed that the GGL domain is sandwiched between the RGS domain and Gb5. 44 Moreover, our finding that DMAP1 binding to the GGL domain of RGS6 is not competitive with Gb5, 8 suggests that the DMAP1-binding surface is between the GGL and RGS domain interface. Thus, Tip60 association with the RGS domain of RGS6 would be on the same surface where we believe Dnmt1 is bound to RGS6, a speculation supported by our finding that RGS6 is required for Tip60-mediated Dnmt1 degradation (Figure 3h) . Interestingly, the RGS domain of Axin was not sufficient for Tip60 binding. 41 We suspect that RGS6 and Axin bind Tip60 differently, in part because Axin possesses an RGS 'like' domain that differs structurally from the RGS domain of canonical RGS proteins including RGS6. Our findings reveal an entirely novel function of the RGS domain, whose only previously known function was to bind and accelerate the GTPase activity of Ga subunits. These results show that the RGS domain of RGS6 functions to scaffold Tip60 near its GGL domain-bound Dnmt1 substrate and raise the intriguing possibility that RGS6 promotes Tip60-mediated Dnmt1 acetylation leading to ubiquitylation and degradation of Dnmt1.
To test the above possibility, we examined the role of RGS6 in Dnmt1 acetylation and ubiquitylation and Tip60-dependent Dnmt1 degradation. First, we compared Dnmt1 acetylation and ubiquitylation in immunoprecipitates from WT and RGS6 À / À MEFs transfected with His-ubiquitin. Acetylation and ubiquitylation of Dnmt1 were greatly reduced in RGS6 À / À vs WT MEFs, consistent with the much greater level of Dnmt1 in RGS6 À / À immunoprecipitates ( Figure 3g ). We next tested the role of RGS6 in Tip60-mediated degradation of Dnmt1 by Tip60 knockdown studies in WT and RGS6 À / À MEFs. Figure 3h shows that Tip60 knockdown with two distinct Tip60 small hairpin RNAs greatly upregulated the low Dnmt1 levels in WT MEFs. In contrast, knockdown of Tip60 had no effect on Dnmt1 expression in RGS6 À / À MEFs. These observations confirm that RGS6 has an essential role in Tip60-mediated degradation of Dnmt1. Moreover, they indicate that Tip60 mediates the suppression of Dnmt1 protein levels by RGS6. These novel findings support a model in which RGS6 promotes association between Dnmt1 and Tip60 by acting as a scaffold protein, thereby mediating Tip60 acetylation of Dnmt1 leading to Dnmt1 ubiquitylation and degradation (Figure 3i ).
In summary, we provide evidence for a new and crucial role for RGS6 in suppression of oncogenic transformation. RGS6 blocks Ras-induced transformation in part by strongly downregulating Dnmt1, a protein that mediates silencing of pro-apoptotic and tumor-suppressor genes. Our finding that RGS6 functions as a scaffold for Tip60 and Dnmt1 to mediate Tip60 acetylation and subsequent degradation of Dnmt1 provides new understanding of the mechanisms responsible for regulating Dnmt1 expression and activity. That Tip60 associates with RGS6 via its RGS domain provides the first evidence for a novel function of the RGS domain beyond its role in G protein regulation. Our findings suggest that loss of RGS6, as we observed during breast cancer progression, 6 may be a mechanism underlying upregulation of Dnmt1 and increases in DNA methylation during carcinogenesis. Indeed, we recently demonstrated a large increase in carcinogen-induced Dnmt1 expression in RGS6 À / À mouse mammary glands compared with WT tissue. 39 Our demonstration of an essential role for RGS6 in blocking oncogenic transformation by promoting Dnmt1 degradation identify RGS6 as a potential therapeutic target for the treatment of human cancers.
